» Articles » PMID: 33718513

GAMER-Ad: a Novel and Rapid Method for Generating Recombinant Adenoviruses

Overview
Publisher Cell Press
Date 2021 Mar 15
PMID 33718513
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Oncolytic adenoviruses have become ideal agents in the path toward treating cancer. Such viruses have been engineered to conditionally replicate in malignant cells in which certain signaling pathways have been disrupted. Other than such oncolytic properties, the viruses need to activate the immune system in order to sustain a long-term response. Therefore, oncolytic adenoviruses have been genetically modified to express various immune-stimulatory agents to achieve this. However, genetically modifying adenoviruses is very time consuming and labor intensive with the current available methods. In this paper, we describe a novel method we have called GAMER-Ad to genetically modify adenovirus genomes within 2 days. Our method entails the replacement of the gp19k gene in the E3 region with any given gene of interest (GOI) using Gibson Assembly avoiding the homologous recombination between the shuttle and the parental plasmid. In this manuscript as proof of concept we constructed and characterized three oncolytic adenoviruses expressing CXCL9, CXCL10, and interleukin-15 (IL-15). We demonstrate that our novel method is fast, reliable, and simple compared to other methods. We anticipate that our method will be used in the future to genetically engineer oncolytic but also other adenoviruses used for gene therapy as well.

Citing Articles

An automated and high-throughput approach for enhanced precision of adenoviral titering.

Bottega P, Fusciello M, Hamdan F, Chiaro J, Russo S, DAlessio F Mol Ther Methods Clin Dev. 2025; 33(1):101410.

PMID: 39968184 PMC: 11834061. DOI: 10.1016/j.omtm.2025.101410.


Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches.

DAmico C, Fusciello M, Hamdan F, DAlessio F, Bottega P, Saklauskaite M Bioact Mater. 2024; 45:115-127.

PMID: 39639878 PMC: 11617629. DOI: 10.1016/j.bioactmat.2024.11.006.


Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses.

Feodoroff M, Hamdan F, Antignani G, Feola S, Fusciello M, Russo S Oncoimmunology. 2024; 13(1):2407532.

PMID: 39351443 PMC: 11441019. DOI: 10.1080/2162402X.2024.2407532.


Combining CRISPR-Cas-mediated terminal resolution with a novel genetic workflow to achieve high-diversity adenoviral libraries.

Fischer J, Fedotova A, Jaki L, Sallard E, Erhardt A, Fuchs J Mol Ther Methods Clin Dev. 2024; 32(2):101241.

PMID: 38585687 PMC: 10995876. DOI: 10.1016/j.omtm.2024.101241.


Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.

Chen L, Zuo M, Zhou Q, Wang Y Front Immunol. 2024; 14:1308890.

PMID: 38169820 PMC: 10758479. DOI: 10.3389/fimmu.2023.1308890.


References
1.
Flint S, Levine A, Sambrook J, Sharp P . Adenovirus transcription. II. RNA sequences complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1- and AD2+ND3-infected cells. J Virol. 1975; 16(3):662-73. PMC: 354714. DOI: 10.1128/JVI.16.3.662-673.1975. View

2.
Hardy S, Kitamura M, Dai Y, Phipps M . Construction of adenovirus vectors through Cre-lox recombination. J Virol. 1997; 71(3):1842-9. PMC: 191254. DOI: 10.1128/JVI.71.3.1842-1849.1997. View

3.
Pitt J, Marabelle A, Eggermont A, Soria J, Kroemer G, Zitvogel L . Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016; 27(8):1482-92. DOI: 10.1093/annonc/mdw168. View

4.
Wold W, Doronin K, Toth K, Kuppuswamy M, Lichtenstein D, Tollefson A . Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol. 1999; 11(4):380-6. DOI: 10.1016/S0952-7915(99)80064-8. View

5.
Evans R, Nawrocki D, Isopi L, Williams D, Casimiro D, Chin S . Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci. 2004; 93(10):2458-75. DOI: 10.1002/jps.20157. View